TY - JOUR ID - 107188 TI - Transfection of Exogenous Fibroblast Growth Factor (FGF) on Human Embryonic Stem Cells (ESCs) as a Regenerative Agent for Patients with Type 1 Diabetes Mellitus (T1DM) JO - International Journal of Medical Reviews JA - IJMR LA - en SN - 2345-525X AU - Nolan, John AU - Wijaya, Audrey AU - Lianto, Agatha AU - Saraswati, Made AD - Medical Faculty of Udayana University, Denpasar, Bali, Indonesia AD - Endocrinology and Metabolism Division, Department of Internal Medicine, Medical Faculty of Udayana University/Sanglah Hospital, Denpasar, Bali, Indonesia Y1 - 2020 PY - 2020 VL - 7 IS - 1 SP - 11 EP - 14 KW - Type 1 Diabetes Mellitus KW - Embryonic Stem Cells KW - Fibroblast Growth Factor-2 DO - 10.30491/ijmr.2020.219730.1077 N2 - Type 1 Diabetes Mellitus (T1DM) is an autoimmune disorder which results in the INS pancreatic β-cell destruction and contributes to around 5 to 10% of all diabetes mellitus cases, especially in children. At the moment, the only treatment for T1DM is by insulin injection, which is injected in order to prevent the complication of T1DM. However, several studies have shown that combination between Embryonic Stem Cells (ESCs) and the Fibroblast Growth Factor 2 (FGF-2) may be a successful modality to treat T1DM. Actually, the ESCs may become the potential therapy in treating T1DM. UR - https://www.ijmedrev.com/article_107188.html L1 - https://www.ijmedrev.com/article_107188_962250c6f8784160026ad46510fdb96d.pdf ER -